The science and technology innovation board opened two years, the performance of medical device enterprises bright

Medical News, August 12th: The Sci-tech Innovation Board was launched in July 2019, and it has been more than two years. According to data from the Shanghai Stock Exchange, as of July 22, there were 313 listed companies on the Science and Technology Innovation Board, with a total market value of 4.95 trillion yuan, and IPO funds raised over 380 billion yuan. As a sunrise industry, the field of medical devices is rising rapidly. Statistics from the Zhongcheng Medical Devices big data platform show that as of July 22, there are 38 medical device companies listed on the Science and Technology Innovation Board, accounting for 12.1% of the number.

The enthusiasm for listing on the IVD enterprise science and technology board is high

After the outbreak of the new crown pneumonia, the demand for in vitro diagnostic (IVD) reagent products has surged, and the in vitro diagnostic industry has developed rapidly with unprecedented momentum. IVD companies have become the "main force" of medical device companies "landing" on the science and technology innovation board. Statistics from the Zhongcheng Medical Devices big data platform show that from the perspective of medical device segmentation, the IVD field has the largest number of listed companies on the Science and Technology Innovation Board, with 16 companies accounting for 42.1%.

The revenue growth of listed companies is one of the indicators that best reflects the market dividend. In 2020, among the top five annual revenues of 38 medical device companies listed on the Science and Technology Innovation Board, there are 3 IVD companies. Among them, Shengxiang Biology and Oriental Biology rank first and second. The company's annual report shows that Shengxiang Bio's revenue increased by 1203.53% year-on-year, and its net profit increased by 6527.9% year-on-year.

Recently, Hotview Bio has recreated a performance myth with a pre-increased net profit of up to 800 times. The announcement from Hotview Biology shows that thanks to the explosive growth of the company's foreign trade orders, the net profit attributable to the parent in the first half of 2021 is expected to be 1.38 billion to 1.60 billion yuan, a year-on-year increase of 70546.05% to 81808.47%.

Stock price welcomes the "main theme of high rise"

In the two years since the opening of the Science and Technology Innovation Board, medical device companies have demonstrated the vitality of the industry's development with a "rising trend" in stock prices.

Statistics from the Zhongcheng medical device big data platform show that since the opening of the Science and Technology Innovation Board, 37 of the 38 listed medical device companies have seen their share prices rise to varying degrees, with an average increase of nearly 300%. Xinmai Medical and Nanwei Medical, as the first two medical device companies to be listed on the Sci-tech Innovation Board, immediately became "100-yuan shares" on the first day of listing.

It is worth noting that as of July 22, among the 37 companies mentioned above, 27 companies had a share price increase of over 100%; 8 companies had a share price increase of over 500%, namely Nanomicro Technology, Bairen Medical, Aibo Medical, Oriental Biology, Xinmai Medical, Haier Biology, Huaxi Biology and Huitai Medical, involving IVD, medical aesthetics and cardiovascular and other fields. Among them, nano and micro technology in the IVD field has the highest increase, with an increase exceeding 1188%. According to the data, Nanomicro Technology is a high-tech enterprise engaged in the preparation and application of high-performance microspheres. It is currently one of the few companies in the world that can simultaneously prepare inorganic and organic high-performance nano-microsphere materials on a large scale. Its independent research and development The preparation technology and products of monodisperse silica gel microspheres, monodisperse polymer microspheres and chiral chromatographic fillers broke the long-term monopoly pattern of foreign companies in the domestic market and filled the domestic gap. Except for Nanomicro Technology, the other 7 companies are industry leaders, and their stock prices have naturally risen.

It is worth noting that, as a subsidiary of the home appliance giant Haier Group's cross-border pharmaceutical industry, Haier Biotech's share price has risen among the top. In terms of scientific and technological innovation, Haier Bio's biomedical cryogenic technology broke the technical barriers of foreign countries and won the National Science and Technology Progress Award for its technology. At present, the company focuses on the technological ecological strategy, innovates and integrates low-temperature storage and Internet of Things technology, and continues to lead the market in four application scenarios such as biobanks, drug and reagent safety, blood safety, and vaccine safety.